- Tonix Pharmaceuticals Holding Corp TNXP announced that it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the FDA for its COVID-19 vaccine candidate.
- Based on the response, the Company expects to begin a Phase 1 study in 1H of 2022.
- TNX-1800 is a live modified horsepox virus vaccine designed to express the Spike protein of the SARS-CoV-2 virus and elicit a predominant T cell response.
- Related Content: Tonix Pharma To Start Mid-Stage Long COVID Trial In Q4.
- Price Action: TNXP shares are up 0.02% at $0.66 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePreclinical Phase
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
